Axsome Therapeutics antidepressant drug could become blockbuster

The major depressive disorder (MDD) market is expected to soar to $7.87 billion by 2029.

An analyst is predicting that Axsome Therapeutics’ novel antidepressant therapy, which was granted Priority Review by FDA on April 26, will become a blockbuster drug.

AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity to treat major depressive disorder (MDD), Axsome said in a

press release


“In clinical trials, AXS-05 has demonstrated rapid and sustained anti-depressive effects, which will enable it to meet some of the key unmet needs that exist in the major depressive disorder (MDD) market for more effective therapies, as well as for therapies with a rapid onset of action,” said Philippa Salter, neurology analyst for GlobalData in a press release. As a result, GlobalData expects “strong uptake” of AXS-05 when it reaches the market.

FDA previously granted Breakthrough Therapy Designation for AXS-05 for the treatment of MDD in March 2019. The FDA also granted Breakthrough Therapy Designation for AXS-05 for a second indication, Alzheimer’s disease agitation, in June 2020.


Controversial nasal depression spray snares new indication

Axsome’s new drug application for AXS-05 is supported by results from two randomized, double-blind, controlled trials of AXS-05 in patients with a confirmed diagnosis of moderate to severe MDD, which demonstrated statistically significant improvements in depressive symptoms with AXS-05 compared to placebo and active controls, respectively, Axsome said.

AXS-05 will have the potential to become a blockbuster drug by 2026 and will boast global sales of around $1.3 billion by 2029, data and analytics firm GlobalData predicts.


FDA requires boxed warning on Singulair

However, AXS-05 is unlikely to become a first-line therapy for MDD, according to Salter. “The current first-line therapies, such as the selective serotonin reuptake inhibitors (SSRIs) and the serotonin-norepinephrine reuptake inhibitor (SNRIs), are very well entrenched in the market and have the advantage of being available as cheap generics, making it challenging for new, more expensive therapies to compete.”

The major depressive disorder (MDD) market is expected to grow from $3.97 billion in 2019 to $7.87 billion by 2029 across eight major markets — US, France, Germany, Italy, Spain, UK, Japan, and Canada — GlobalData said in a separate report,

Major Depressive Disorder – Global Drug Forecast and Market Analysis to 2029


The main driver of growth will be the launch of eight new pipeline products throughout the eight major markets, GlobalData said.

Read more:

Breakthrough nasal spray for depression not without risks

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Incubators- operating a content network of several thousand sites while federating 20+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $15M+ in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Discover our work!